Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3045 results about "Kinase" patented technology

In biochemistry, a kinase is an enzyme that catalyzes the transfer of phosphate groups from high-energy, phosphate-donating molecules to specific substrates. This process is known as phosphorylation, where the substrate gains a phosphate group and the high-energy ATP molecule donates a phosphate group. This transesterification produces a phosphorylated substrate and ADP. Conversely, it is referred to as dephosphorylation when the phosphorylated substrate donates a phosphate group and ADP gains a phosphate group (producing a dephosphorylated substrate and the high energy molecule of ATP). These two processes, phosphorylation and dephosphorylation, occur four times during glycolysis. Kinases are part of the larger family of phosphotransferases. Kinases should not be confused with phosphorylases, which catalyze the addition of inorganic phosphate groups to an acceptor, nor with phosphatases, which remove phosphate groups. The phosphorylation state of a molecule, whether it be a protein, lipid, or carbohydrate, can affect its activity, reactivity, and its ability to bind other molecules. Therefore, kinases are critical in metabolism, cell signalling, protein regulation, cellular transport, secretory processes, and many other cellular pathways, which makes them very important to human physiology.

Phosphoinositide 3-kinase allosteric inhibitor for treating disease related to PI3k regulation

Disclosed in the present invention is a phosphoinositide 3-kinase allosteric inhibitor for treating a disease related to PI3K regulation. Specifically, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The phosphoinositide 3-kinase allosteric inhibitor of the present invention can effectively conduct allosteric targeted inhibition on a PI3Kα mutation, in particular, a PI3KαH1047R mutation, has relatively good selectivity, and is expected to treat and / or prevent related diseases or disorders.
Owner:SHANGHAI ALLIST PHARM CO LTD

Cyclic peptide compounds and compositions as ras inhibitors

This disclosure provides cyclic peptide compounds of formula (A) or formula (II) as inhibitors of Ras kinase, and compositions and use of the same in treating diseases associated with Ras kinase.
Owner:SYNERON TECHNOLOGY CO LTD +1

Recombinant escherichia coli THRS-6 and method for synthesizing L-threonine by using recombinant escherichia coli THRS-6

ActiveCN119286756ABacteriaHaemoglobins/myoglobinsDeinococcusNucleotide
The invention relates to recombinant escherichia coli THRS-6 and a method for synthesizing L-threonine by using the recombinant escherichia coli THRS-6. The invention belongs to the technical field of bioengineering, and relates to an aspartic acid kinase thrAmut and pyridine nucleotide transhydrogenase pntAB gene derived from escherichia coli, an aspartic acid dehydrogenase aspDH gene derived from pseudomonas aeruginosa, a hemoglobin vgb gene derived from vitreoscilla and a transcriptional regulation factor irrE gene derived from radiococcus. The recombinant escherichia coli is used as a substrate, the ldhA gene is knocked out to further modify the recombinant escherichia coli, the recombinant escherichia coli THRS-6 with glucose as the substrate is obtained, the THRS-6 is used for fermentation, and the yield and conversion rate of the L-threonine are obviously improved.
Owner:QIQIHAR LONGJIANG FUFENG BIOTECHNOLOGIES CO LTD +1

Engineering bacterium for co-expressing D-mannitol dehydrogenase and D-glucose dehydrogenase and application

The invention discloses construction and application of an engineering bacterium for co-expressing D-mannitol dehydrogenase and D-glucose dehydrogenase, and belongs to the technical field of genetic engineering. The technical problem to be solved by the invention is how to co-express D-mannitol dehydrogenase and D-glucose dehydrogenase through a biosynthetic pathway. In order to solve the technical problem, the invention provides recombinant escherichia coli. The recombinant escherichia coli is characterized by containing a D-mannitol dehydrogenase gene, a D-glucose dehydrogenase gene, a glucokinase gene, an acetyl coenzyme A synthetase gene, a D-lactose transporter gene, a D-glucose PTS permease-free gene and a pyruvate oxidase-free gene. And no regulator gene of galactose operon is contained. The invention establishes a preparation method for co-producing D-mannitol and sodium gluconate, which has guiding significance for the production of D-mannitol and sodium gluconate.
Owner:MICROCYTO BIOTECHNOLOGY (BEIJING) CO LTD

Salt forms of IRAK4 degraders

PCT designated stage expiredWO2025080300A1AntipyreticAnalgesicsDiseaseReceptor
The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and / or degradation and uses of the same in the treatment various diseases.
Owner:KYMERA THERAPEUTICS INC

Treatment of lung cancer using a combination of an Anti-PD-1 antibody and another Anti-cancer agent

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
Owner:BRISTOL MYERS SQUIBB CO

Combination therapies

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
Owner:MIRATI THERAPEUTICS INC

Substituted piperidinediones for targeted protein degradation

PCT designated stage expiredWO2025024521A1Organic active ingredientsAntipyreticInterstitial lung diseasePericarditis
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.
Owner:MONTE ROSA THERAPEUTICS AG

Tricyclic triazolo compounds as DGK inhibitors

The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
Owner:INCYTE CORP

Recombinant strain for producing chondroitin sulfate at high yield, application of recombinant strain and preparation method of chondroitin sulfate

ActiveCN119410566AFungiBacteriaPhosphoglucosamine mutaseCarbon metabolism
The invention belongs to the technical field of chondroitin sulfate biosynthesis, and discloses a recombinant strain for high-yield chondroitin sulfate, application of the recombinant strain and a preparation method of the chondroitin sulfate. The recombinant strain provided by the invention can be used for simultaneously expressing UDP-glucosamine isomerase, UDP-glucose dehydrogenase, chondroitin polymerase, glucosamine synthetase, phosphoglucosamine mutase, UDP-N-acetylglucosamine pyrophosphorylase, glucose-6-phosphate isomerase and glucose phosphate mutase; according to the present invention, glucose-1-phosphate uridyl transferase, ATP sulfonase, sulfotransferase, pyruvate kinase and APS kinase are adopted, and the enzyme molecules are matched with the original carbon metabolism pathway in the recombinant strain cell to jointly form the enzyme-linked pathway having the efficient CSA synthesis ability, such that the high-yield and high-purity preparation of the CSA can be achieved; the method has the advantages of simple operation, high biological safety of the obtained product, easy realization of large-scale production and the like, and has a good application prospect.
Owner:INNER MONGOLIA KINGDOMWAY PHARMA LTD +2

Increased production of acetyl-coenzyme a and derived products in yeasts

The present disclosure provides a recombinant yeast host cell having a plurality of native and / or heterologous enzymes that function in an engineered metabolic pathway to convert fructose-6-phosphate to acetyl-coenzyme A. The recombinant yeast host cell can be used, for example, in a process for making acetyl-coenzyme A, acetone and / or isopropanol. The plurality of native and / or heterologous enzymes is activated, upregulated, or overexpressed. The plurality of native and / or heterologous enzymes comprises a phosphoketolase; and optionally an acetate kinase; and / or a phosphotransacetylase. The recombinant yeast host cell comprises at least one of: at least two copies of a heterologous nucleic acid molecule encoding the phosphoketolase; a native and / or heterologous enzyme that functions in an engineered non-oxidative pentose phosphate pathway, wherein the native and / or heterologous enzyme is activated, upregulated, or overexpressed; and / or a native and / or heterologous protein that functions in an engineered metabolic pathway to convert pantothenate into acetyl-coenzyme A, wherein the native and / or heterologous protein is activated, upregulated or overexpressed and comprises at least one of: FEN2 or CAB1.
Owner:DANSTAR FERMENT AG +1

Recombinant pichia pastoris strain for producing astaxanthin as well as construction method and application of recombinant pichia pastoris strain

PendingCN119120242AImprove the ability to produce astaxanthinefficient synthesisFungiStable introduction of DNAPichia pastorisAstaxanthin
The invention relates to a recombinant pichia pastoris strain for producing astaxanthin as well as a construction method and application of the recombinant pichia pastoris strain. The recombinant pichia pastoris strain is obtained by expressing dehydrogenase Zwf1, phosphate dehydrogenase Gnd2, NADH kinase Pos5 and fusion protein CrtZ-Linker-CrtW of beta-carotene ketolase CrtW and beta-carotene hydroxylase CrtZ in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified strain PP-L. The fermentation conditions of the recombinant strain are optimized based on cofactor engineering, and the astaxanthin production capacity of the pichia pastoris is further improved. The construction method of the recombinant pichia pastoris is simple, synthesis of astaxanthin can be better promoted, the engineering strain can efficiently synthesize astaxanthin by using glucose and methanol through fermentation optimization, and industrial production is facilitated.
Owner:NANJING TECH UNIV +1

Substituted tetrazolyl compounds as T cell activators

Disclosed are compounds of formula (I): # imgabs0 # or a salt thereof, wherein: X, Y, Z, R1, R2, R3 and n are as defined herein. Also disclosed are methods of inhibiting the activity of one or both of diacylglycerol kinase alpha (DGK alpha) and diacylglycerol kinase zeta (DGK zeta) using such compounds, as well as pharmaceutical compositions comprising such compounds. These compounds are useful for the treatment of viral infections and proliferative diseases such as cancer.
Owner:BRISTOL MYERS SQUIBB CO

Reagent and kit for detecting creatine kinase and application

The invention belongs to the technical field of creatine kinase detection kits, and particularly relates to a creatine kinase detection reagent, a creatine kinase detection kit and application, the creatine kinase detection reagent comprises a buffer solution, creatine phosphate, glycerol, glycerol kinase, glycerophosphate oxidase, peroxidase and a color developing agent, and further comprises a CK activation reducing agent and perfluoro and polyfluoroalkyl substances, the CK activation reducing agent is a sulfur-containing reducing agent. According to the method, the detection accuracy can be improved.
Owner:HUNAN NORMAL UNIVERSITY

Recombinant pichia pastoris strain with high astaxanthin yield as well as construction method and application of recombinant pichia pastoris strain

PendingCN120682959AFungiMicroorganism based processesPichia pastorisCholine kinase
The invention relates to a recombinant pichia pastoris strain capable of producing astaxanthin at high yield as well as a construction method and application of the recombinant pichia pastoris strain. The recombinant pichia pastoris strain is obtained by expressing ATP (adenosine triphosphate) citrate lyase (ACL) and acetyl-CoA synthase (ACS) or phosphoketolase (PK) and phosphotransacetylase (PTA), choline kinase (CK), inositol polyphosphate kinase (IPK) and vitreoscilla hemoglobin (VHB) in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified strain PP-LC2. The astaxanthin production performance of the recombinant strain is verified on the basis of comparison of precursor supply pathways, IUP pathway construction and improvement of the oxygen supply capacity of the engineering strain, and the astaxanthin production capacity of the pichia pastoris is further improved. The construction method of the recombinant pichia pastoris is simple, the synthesis of astaxanthin can be better promoted, the engineering strain can efficiently synthesize the astaxanthin by utilizing methanol through amplification fermentation of a 5L fermentation tank, and industrial production is facilitated.
Owner:NANJING TECH UNIV

Class of programmed cell death inhibitors, preparation method therefor and use thereof

PCT designated stage expiredWO2025007938A1Senses disorderAntibacterial agentsDiseasePharmaceutical drug
The present invention provides a class of programmed cell death inhibitors, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, the compound being as shown in Formula I. The present invention also provides a method for preparing the compound and a pharmaceutical composition comprising the compound or a use thereof in treating or preventing diseases or conditions associated with programmed cell death and / or human receptor-interacting protein 1 kinase (RIPK1).
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI

Inhibitor compound, application and medicine for treating cancer

The invention belongs to the technical field of medicine synthesis, and particularly relates to an inhibitor compound, application and a medicine for treating cancer. The invention provides an inhibitor compound or a pharmaceutically acceptable salt, which can be used for preparing an EGFR kinase inhibitor and preparing a medicine for treating or preventing cancers. The present invention also provides medicaments for the treatment of cancer comprising the inhibitor compound or a pharmaceutically acceptable salt. The compound or the medicine provided by the invention is efficient and low in toxicity, not only has higher anti-tumor activity and can effectively inhibit the growth of cancer cells, but also keeps higher brain permeability, and has wide application prospects.
Owner:ANHUI PHARMAMAX BIOTECH CO LTD

Genetically engineered bacterium for producing uridine diphosphate glucose as well as construction method and application of genetically engineered bacterium

The invention discloses a genetically engineered bacterium for producing uridine diphosphate glucose as well as a construction method and application of the genetically engineered bacterium, and belongs to the technical field of genetic engineering. The following genes are overexpressed in the genetically engineered bacterium: a pyrimidine nucleoside operon gene, a carbamyl phosphate synthetase gene, an aspartate carbamyl transaminase gene, an orotic acid phosphoribose transferase gene, a phosphoribose pyrophosphate synthase gene, a uridylate kinase gene and a glucophosphate mutase gene. A uridine triphosphate glucose-1-phosphate uridine group transferase gene; the genetically engineered bacterium does not express the following genes: a purine nucleotide repressor protein gene, a deoxyribonucleoside triphosphate reductase gene, a nucleoside triphosphate pyrophosphohydrolase gene, a cytidine triphosphate synthase gene, a pyrimidine nucleotidase gene, a nucleotidase gene, an ornithine carbamoyltransferase gene, a UDPG dehydrogenase gene and a lacI repressor protein gene. The genetically engineered bacterium can be used for efficiently synthesizing UDPG by taking glucose as a substrate.
Owner:ZHUCHENG HAOTIAN PHARMA CO LTD

Talaromyces purpurogenum D2 and application thereof

The invention relates to talaromyces purpurogenus D2 and application thereof, and belongs to the technical field of microorganisms. The talaromyces purpurogenus D2 disclosed by the invention has the preservation number of GDMCC (Graphics Decific Microorganism Center) NO.66320 The strain is obtained by being separated from soil and domesticated, the zinc tolerance concentration of the strain can reach 2g / L, and the strain can efficiently convert inorganic zinc into organic active zinc which can be easily absorbed and utilized by a human body. The organic zinc prepared from the strain has a remarkable ABTS free radical scavenging capability, and also has tyrosine kinase and 5-alpha reductase inhibition capability; the organic zinc prepared from the talaromyces purpurogenum D2 can be used for preparing zinc-supplementing health-care products, can also be used as cosmetic active matter raw materials with free radical scavenging and whitening effects, and has a wide market application prospect.
Owner:GUANGZHOU AIZHUO BIOTECHNOLOGY CO LTD

Cyclin-dependent kinase 2 degraders

The present disclosure provides a compound represented by structural Formula (I): Formula (I), or a pharmaceutically acceptable salt thereof. Compounds of the disclosure are useful for degrading cyclin-dependent kinases (CDKs) and for treating diseases and disorders mediated by CDKs.
Owner:BLUEPRINT MEDICINES CORP

Construction method and application of genetically engineered bacterium for efficiently producing O-acetyl-L-homoserine

The invention relates to the technical field of microbial metabolism engineering, in particular to a construction method and application of genetically engineered bacteria for efficiently producing O-acetyl-L-homoserine. The construction method specifically comprises the following steps: (1) taking a strain Escherichia coli W3110 as a chassis, and knocking out a homoserine O-succinyl transferase coding gene metA; (2) knocking out a gamma-cystathionine synthetase encoding gene metB; (3) knocking out a cysteine lyase coding gene metC; (4) carrying out weakening expression on an O-acetyl-L-homoserine thiolase coding gene metYcm from the marine cyclobacterium; (5) overexpressing a ribulose diphosphate carboxylase coding gene rbcLSse from the synechococcus elongate; (6) overexpressing a ribulose phosphate kinase coding gene prkse from the synechococcus slender; and (7) weakening the expression of the citrate synthase coding gene gltA to obtain the genetically engineered bacterium for efficiently producing the O-acetyl-L-homoserine. The strain provided by the invention is used for producing O-acetyl-L-homoserine, and has the advantages of high yield, high yield and high sugar-acid conversion rate.
Owner:ZHEJIANG UNIV OF TECH

Methods for treating prostate and lung cancer

The current disclosure is centered on the hypothesis that a better understanding of the neuroendocrine transdifferentiation (NEtD) process will provide therapeutic targets for inhibiting this transition and thus improving standard of care therapies. Accordingly, the current disclosure provides for a method for treating cancer in a subject, the method comprising administering an inhibitor of a gene, wherein the gene comprises one or more of tenascin C (TNC), advillin (AVIL), S100A7, PPARG, LOX lysyl oxidase, KLF5, APOBEC2, FOSL1, FOXM1, hedgehog, RELA, p65, IKK complex, JAK, STAT, TFAP4, geminin, OCA-1, OCA-2, Nf-kB, Nf-kB family and associated regulators, angiogenesis regulators such as BMX kinase, TEK kinase, periostin (POSTN), and VEGF family, stress genes, such as the JUN / FOS family, a gene from the S100 family, and cell state regulators such as ASCL1, POU2F3, NEUROD1, ASCL2, and YAP1.
Owner:RGT UNIV OF CALIFORNIA

Method for synthesizing S-sulfo-L-cysteine through multi-enzyme cascade catalysis

The invention relates to the technical field of biology, in particular to a method for synthesizing S-sulfo-L-cysteine through multi-enzyme cascade catalysis. The invention provides a new route for biosynthesis of S-sulfo-L-cysteine, and a test result shows that serine, AMP, sodium hexametaphosphate and sodium thiosulfate are used as substrates, and the S-sulfo-L-cysteine is synthesized by a one-step method. A crude enzyme liquid which contains serine kinase, polyphosphoric acid-AMP phosphotransferase and phosphoserine dependent type S-sulfo-L-cysteine synthetase in which the background of tryptophanase and glutaredoxin cells is knocked out is used for synthesizing the S-sulfo-L-cysteine, the steps are simple, the product yield is high, the cost is low, and the method has a relatively strong industrial application prospect.
Owner:SHENZHEN READLINE BIOTECH CO LTD

Uracil production strain as well as construction method and application thereof

The invention relates to the technical production field of metabolic engineering and genetic engineering, and particularly provides a uracil production strain as well as a construction method and application thereof. According to the strain, a uridine kinase gene udk is knocked out on an E.coli W3110 genome, and meanwhile, a T7RNA polymerase gene is integrated; the uridine monophosphate kinase gene pyrH is weakened; the method comprises the following steps: overexpressing a carbamyl phosphate synthetase gene carAB, a ribose phosphate pyrophosphate kinase gene prsA, a pyrimidine-5 '-nucleoside enzyme gene ppnN, UMP phosphohydrolase genes umpH and umpG, a ribonucleoside hydrolase 1 gene rihA and a glutamine synthetase gene glnA; an orotic acid nucleoside monophosphate decarboxylase gene pyrF and an orotic acid ribosyltransferase gene pyrE of wild type bacillus subtilis B.subtilis 168 are introduced in a heterologous manner, so that an orotate nucleoside monophosphate decarboxylase gene pyrF and an orotate ribosyltransferase gene pyrE are obtained. The safe, efficient and low-cost production of the uracil is realized.
Owner:新疆瑞诺生物科技有限公司

Biomarker for predicting curative effect of non-small cell lung cancer immunotherapy and application thereof

The invention relates to a biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and SERPINE1 mRNA binding protein 1 (SERBP1). The biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)

ROR / EGFR bispecific antigen binding molecules

The present invention relates to bispecific antigen binding molecules specific for both the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the epidermal growth factor receptor (EGFR), as well as related fusion proteins and conjugates. In another aspect, the invention relates to conjugated immunoglobulin-like shark variable neoantigen receptors (VNARs).
Owner:ALMAC DISCOVERY LIMITED